In our cohort, all rates of selected OSDs markedly decreased as HAART use increased. Our data support the conclusion that thrombocytopenia in children responds to HAART treatment, as has already been described GSK2126458 clinical trial in

adults [26]. Despite the scarcity of information in children, there is one report of three cases in which peripheral cytopenias improved under HAART [27]. Nevertheless, larger studies are needed to determine the effects of HAART on haemopoietic cell abnormalities in the paediatric population. A dramatic decrease in the rate of HIV-related wasting syndrome has been observed in our cohort as the use of HAART has increased. In the adult population, weight loss and wasting remain important AIDS-defining conditions independently associated with mortality, despite the advent of HAART [28]. Other authors have recently observed

that the early use of HAART may prevent the development of chronic lung disease in children [29,30]. Lymphoid interstitial pneumonia has been described to improve as a result of HAART [31] or as a clinical manifestation of the immune reconstitution inflammatory syndrome [32]. This last effect was not observed in our patients, while the significant decrease in the rate of lymphoid interstitial pneumonia was attributed to the widespread use of HAART. Similarly, in our series, the decrease in cardiomyopathy may be attributed mainly to the use of HAART, as dilated cardiomyopathy was the only HIV-associated event recorded. However, in HAART-treated adult series, additional cardiovascular selleck kinase inhibitor consequences have been described as a result of the metabolic syndrome with a propensity for hyperlipidaemia. The involvement of the cardiovascular system is of major concern in HIV-infected children as the long-term consequences associated with atherosclerotic heart disease are unknown [33,34]. The frequency of the most severe

forms of HIV-associated encephalopathy among children has dropped dramatically since the introduction of HAART in our patients. Of concern, however, is the L-NAME HCl possibility that a more insidious form of this disorder, with residual neurological, cognitive and learning impairments, may currently be occurring among older vertically infected children as a result of inadequate penetration of the antiretroviral agents into the cerebrospinal fluid [35,36]. Thus, early predictive markers for the prompt and reliable identification of infants who are at risk for encephalopathy are needed [37]. Finally, our study had several limitations, such as the heterogeneous collection of data, both retrospective and prospective, and the lack of a direct relationship between HAART and clinical manifestations, CD4 cell counts and HIV viral loads in every CP.